Entera Bio Ltd. (ENTX) shareholders
Close on Nov 17, 2026Market cap $519.43MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 17,225,121 | 9.99% | 13D (active) | Jul 28, 2026 |
| Chen Yu Joint filing with TCG Crossover GP III, LLC (7.10%), TCG Crossover Fund III, L.P. (7.10%) | 12,254,901 | 7.10% | 13G (passive) | Jul 28, 2026 |
| Vivo Opportunity, LLC | 11,817,401 | 6.90% | 13G (passive) | Jul 28, 2026 |
| Bong Y. Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.10%), VHCP Co-Investment Holdings III, LLC (5.10%) and 4 more | 8,861,763 | 5.10% | 13G (passive) | Oct 23, 2026 |
| Knoll Capital Management, LLC Joint filing with Fred Knoll (15.00%), Gakasa Holdings, LLC (15.00%) | 5,881,879 | 15.00% | 13G (passive) amendment | Nov 14, 2024 |
| Opko Health, Inc. | 3,685,226 | 8.10% | 13G (passive) | Mar 16, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (6.80%), Steven A. Cohen (6.80%) | 2,701,560 | 6.80% | 13G (passive) | Jan 3, 2025 |
| Centillion Fund, Inc. | 2,396,953 | 6.70% | 13G (passive) amendment | Jul 19, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,881,879 | 3.40% | $10.41M | – | 5.81% |
| Bvf Inc/Il | 2,425,000 | 1.40% | $4.29M | New | 0.11% |
| Siren, L.L.C. | 736,457 | 0.43% | $1.30M | New | 0.03% |
| Renaissance Technologies LLC | 368,847 | 0.21% | $652.86K | −104,595 | 0.00% |
| Parkman Healthcare Partners LLC | 274,497 | 0.16% | $485.86K | −14,173 | 0.05% |
| PNC Financial Services Group, Inc. | 273,031 | 0.16% | $483.27K | +263,031 | 0.00% |
| Seven Fleet Capital Management LP | 191,354 | 0.11% | $338.70K | −14,188 | 0.06% |
| HighTower Advisors, LLC | 74,573 | 0.04% | $132.94K | +37,743 | 0.00% |
| Hrt Financial LP | 72,486 | 0.04% | $128.00K | +56,994 | 0.00% |
| Schonfeld Strategic Advisors LLC | 58,871 | 0.03% | $104.20K | +3,648 | 0.00% |
| Two Sigma Securities, LLC | 48,593 | 0.03% | $86.01K | New | 0.01% |
| Signature Estate & Investment Advisors LLC | 47,328 | 0.03% | $83.77K | – | 0.00% |
| JPMorgan Chase & Co | 40,883 | 0.02% | $67.46K | +33,733 | 0.00% |
| Citadel Advisors LLC | 38,804 | 0.02% | $68.68K | −206,773 | 0.00% |
| Virtu Financial LLC | 36,921 | 0.02% | $65.00K | New | 0.00% |
| Geode Capital Management, LLC | 29,908 | 0.02% | $52.94K | +8,772 | 0.00% |
| Diadema Partners LP | 23,260 | 0.01% | $41.17K | – | 0.01% |
| XTX Topco Ltd | 20,559 | 0.01% | $36.39K | −111,063 | 0.00% |
| Gem Investment Advisors, LLC | 19,135 | 0.01% | $33.87K | – | 0.02% |
| Jane Street Group, LLC | 17,331 | 0.01% | $30.68K | −15,584 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 11M | 6.2% | 7 / 8 | 6 / 6 | 4M | 1M |
| Q1 2026 | 26 | 8M | 4.5% | 8 / 5 | 7 / 4 | 1M | 2M |
| Q4 2025 | 22 | 9M | 5.4% | 5 / 6 | 4 / 4 | 0M | 0M |
| Q3 2025 | 22 | 9M | 5.3% | 4 / 5 | 7 / 1 | 1M | 2M |
| Q2 2025 | 19 | 10M | 5.9% | 4 / 5 | 3 / 3 | 0M | 0M |
| Q1 2025 | 18 | 10M | 5.9% | 4 / 4 | 3 / 0 | 3M | 0M |
| Q4 2024 | 14 | 7M | 4.3% | 2 / 5 | 2 / 5 | 2M | 0M |
| Q3 2024 | 17 | 5M | 3.1% | 3 / 3 | 3 / 1 | 0M | 0M |
| Q2 2024 | 15 | 5M | 3.1% | 5 / 2 | 3 / 5 | 1M | 0M |
| Q1 2024 | 15 | 4M | 2.5% | 7 / 3 | 1 / 2 | 0M | 0M |
| Q4 2023 | 10 | 4M | 2.3% | 2 / 3 | 1 / 4 | 2M | 0M |
| Q3 2023 | 12 | 3M | 1.5% | 3 / 3 | 3 / 3 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Miranda Jayne Toledano | Chief Executive Officer, Director | 847,135 | 0.49% | Aug 7, 2026 |
| Riccardo Paolo Camisasca | Chief Medical Officer | – | – | Aug 21, 2026 |
| Hillel Galitzer | Chief Operating Officer | 163,566 | 0.09% | Aug 7, 2026 |
| Gregory Burshtein | Chief of R&D | 189,033 | 0.11% | Aug 7, 2026 |
| Dana Yaacov-Garbeli | Chief Financial Officer | 258,172 | 0.15% | Aug 7, 2026 |
| Leslie Velka Gautam | Chief Business Officer | – | – | May 20, 2025 |
| Yonatan Malca | Director | 100,231 | 0.06% | Aug 7, 2026 |
| Haya Taitel | Director | 119,269 | 0.07% | Aug 7, 2026 |
| Steven D. Rubin | Director | 34,117 | 0.02% | Aug 7, 2026 |
| Sean Ellis | Director | 208,132 | 0.12% | Aug 7, 2026 |
| Geno J. Germano | Director | 65,014 | 0.04% | Aug 7, 2026 |
| Gerald M. Ostrov | Director | 75,657 | 0.04% | Jan 2, 2026 |
| Gerald M. Lieberman | Director | 344,654 | 0.20% | Jan 2, 2026 |
| Knoll Capital Management, LLC | 10% owner | 5,534,275 | 3.20% | Nov 20, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sean Ellis Director | Aug 7, 2026 | Award | +20,034 | – | – | 208,132 |
| Yonatan Malca Director | Aug 7, 2026 | Award | +22,815 | – | – | 100,231 |
| Steven D. Rubin Director | Aug 7, 2026 | Award | +19,117 | – | – | 34,117 |
| Haya Taitel Director | Aug 7, 2026 | Award | +20,790 | – | – | 119,269 |
| Geno J. Germano Director | Aug 7, 2026 | Award | +25,014 | – | – | 65,014 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 14, 2026 | Award | +72,993 | – | – | 847,135 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 14, 2026 | Award | +347,567 | – | – | 774,142 |
| Dana Yaacov-Garbeli Chief Financial Officer | May 7, 2026 | Award | +58,394 | – | – | 171,441 |
| Gregory Burshtein Chief of R&D | May 7, 2026 | Award | +87,591 | – | – | 189,033 |
| Hillel Galitzer Chief Operating Officer | May 7, 2026 | Award | +72,993 | – | – | 163,566 |
| Geno J. Germano Director | Mar 9, 2026 | Buy | +20,000 | $1.30 | $26.00K | 40,000 |
| Sean Ellis Director | Mar 5, 2026 | Buy | +10,000 | $1.23 | $12.30K | 188,098 |
| Steven D. Rubin Director | Feb 12, 2026 | Buy | +5,000 | $1.49 | $7.45K | 15,000 |
| Geno J. Germano Director | Feb 10, 2026 | Buy | +20,000 | $1.49 | $29.80K | – |
| Haya Taitel Director | Feb 10, 2026 | Buy | +7,500 | $1.48 | $11.10K | – |
| Sean Ellis Director | Feb 9, 2026 | Buy | +18,000 | $1.24 | $22.32K | 178,098 |
| Steven D. Rubin Director | Feb 9, 2026 | Buy | +10,000 | $1.20 | $12.00K | 10,000 |
| Haya Taitel Director | Jan 1, 2026 | Award | +26,329 | – | – | 90,979 |
| Gerald M. Ostrov Director | Jan 1, 2026 | Award | +28,721 | – | – | 75,657 |
| Gerald M. Lieberman Director | Jan 1, 2026 | Award | +38,294 | – | – | 338,454 |
| Yonatan Malca Director | Jan 1, 2026 | Award | +30,157 | – | – | 77,416 |
| Sean Ellis Director | Jan 1, 2026 | Award | +25,371 | – | – | 160,098 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Dec 29, 2025 | Buy | +11,000 | $1.81 | $19.91K | 426,575 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 16, 2025 | Award | +136,842 | – | – | 371,715 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 16, 2025 | Award | +43,860 | – | – | 415,575 |
| Gregory Burshtein Chief of R&D | Jul 16, 2025 | Award | +26,316 | – | – | 101,442 |
| Dana Yaacov-Garbeli Chief Financial Officer | Jul 16, 2025 | Award | +26,316 | – | – | 113,047 |
| Hillel Galitzer Chief Operating Officer | Apr 28, 2025 | Award | +26,316 | – | – | 90,573 |
| Gerald M. Lieberman Director | Apr 1, 2025 | Option exercise | +23,952 | $1.00 | $23.95K | 300,160 |
| Gerald M. Ostrov Director | Jan 15, 2025 | Award | +8,038 | – | – | 46,936 |
| Gerald M. Lieberman Director | Jan 15, 2025 | Award | +10,717 | – | – | 276,208 |
| Yonatan Malca Director | Jan 15, 2025 | Award | +8,216 | – | – | 47,259 |
| Sean Ellis Director | Jan 15, 2025 | Award | +7,100 | – | – | 134,727 |
| Haya Taitel Director | Jan 15, 2025 | Award | +6,922 | – | – | 64,650 |
| Haya Taitel Director | Oct 2, 2024 | Award | +7,278 | – | – | 57,728 |
| Gerald M. Ostrov Director | Oct 2, 2024 | Award | +8,452 | – | – | 38,898 |
| Sean Ellis Director | Oct 2, 2024 | Award | +7,466 | – | – | 127,627 |
| Yonatan Malca Director | Oct 2, 2024 | Award | +8,639 | – | – | 39,043 |
| Gerald M. Lieberman Director | Oct 2, 2024 | Award | +11,269 | – | – | 265,491 |
| Gerald M. Lieberman Director | Aug 27, 2024 | Award | +27,261 | – | – | 254,222 |
| Gerald M. Ostrov Director | Aug 27, 2024 | Award | +20,446 | – | – | 30,446 |
| Haya Taitel Director | Aug 27, 2024 | Award | +15,335 | – | – | 50,450 |
| Sean Ellis Director | Aug 27, 2024 | Award | +18,061 | – | – | 120,161 |
| Yonatan Malca Director | Aug 27, 2024 | Award | +23,172 | – | – | 30,404 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 31, 2024 | Award | +124,121 | – | – | 234,873 |
| Dana Yaacov-Garbeli Chief Financial Officer | Apr 19, 2024 | Award | +30,151 | – | – | 86,731 |
| Hillel Galitzer Chief Operating Officer | Apr 19, 2024 | Award | +30,151 | – | – | 64,257 |
| Dana Yaacov-Garbeli Chief Financial Officer | Apr 19, 2024 | Award | +30,151 | – | – | 86,731 |
| Haya Taitel Director | Jan 12, 2024 | Buy | +9,500 | $0.99 | $9.41K | 35,115 |
| Haya Taitel Director | Jan 10, 2024 | Buy | +7,615 | $0.77 | $5.86K | 25,615 |
| Gerald M. Lieberman Director | Dec 22, 2023 | Buy | +23,952 | $0.71 | $17.01K | 226,961 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Dec 22, 2023 | Buy | +23,952 | $0.71 | $17.01K | 110,752 |
| Haya Taitel Director | Aug 22, 2023 | Buy | +18,000 | $0.62 | $11.16K | 18,000 |
| Gerald M. Lieberman Director | Aug 21, 2023 | Buy | +20,000 | $0.59 | $11.80K | 214,209 |
| Sean Ellis Director | Aug 21, 2023 | Buy | +40,000 | $0.60 | $24.00K | 102,100 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Apr 4, 2023 | Buy | +30,000 | $1.01 | $30.30K | 86,800 |
| Dana Yaacov-Garbeli Chief Financial Officer | Nov 14, 2022 | Buy | +26,580 | $0.54 | $14.35K | 56,580 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +34,000 | $0.57 | $19.38K | 194,209 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +4,000 | $0.56 | $2.24K | 6,200 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +4,000 | $0.56 | $2.24K | 6,200 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Entera Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 133,414 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?